ScoreWhy is Tasly Pharmaceutical Group Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of -14.46% and Operating profit at -7.68% over the last 5 years
2
Flat results in Jun 25
- OPERATING CASH FLOW(Y) Lowest at CNY 1,947.94 MM
3
With ROE of 7.88%, it has a very attractive valuation with a 1.96 Price to Book Value
- Over the past year, while the stock has generated a return of 4.22%, its profits have fallen by -17.5%
- At the current price, the company has a high dividend yield of 3.3
4
Underperformed the market in the last 1 year
- The stock has generated a return of 4.22% in the last 1 year, much lower than market (China Shanghai Composite) returns of 14.77%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Tasly Pharmaceutical Group Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Tasly Pharmaceutical Group Co., Ltd. for you?
Low Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Tasly Pharmaceutical Group Co., Ltd.
4.22%
0.57
20.41%
China Shanghai Composite
14.77%
1.01
14.58%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-14.46%
EBIT Growth (5y)
-7.68%
EBIT to Interest (avg)
15.07
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
0.56
Tax Ratio
16.92%
Dividend Payout Ratio
82.86%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
9.92%
ROE (avg)
10.17%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
1.96
EV to EBIT
20.19
EV to EBITDA
14.02
EV to Capital Employed
2.20
EV to Sales
2.63
PEG Ratio
NA
Dividend Yield
3.27%
ROCE (Latest)
10.91%
ROE (Latest)
7.88%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -0.44% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -19.58 %
NET PROFIT(Q)
At CNY 427.57 MM has Grown at 61.3%
EPS(Q)
Highest at CNY 0.31
-2What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at CNY 1,947.94 MM
Here's what is working for Tasly Pharmaceutical Group Co., Ltd.
Net Profit
At CNY 427.57 MM has Grown at 61.3%
over average net sales of the previous four periods of CNY 265.08 MMMOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
EPS
Highest at CNY 0.31
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CNY)
Debt-Equity Ratio
Lowest at -19.58 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -0.44% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Tasly Pharmaceutical Group Co., Ltd.
Operating Cash Flow
Lowest at CNY 1,947.94 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (CNY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
